Journal of Inherited Metabolic Disease最新文献

{"title":"iPSC-Derived Liver Organoids as a Tool to Study Medium Chain Acyl-CoA Dehydrogenase Deficiency","authors":"Ligia A. Kiyuna,&nbsp;José M. Horcas-Nieto,&nbsp;Christoff Odendaal,&nbsp;Miriam Langelaar-Makkinje,&nbsp;Albert Gerding,&nbsp;Mathilde J. C. Broekhuis,&nbsp;Flavio Bonanini,&nbsp;Madhulika Singh,&nbsp;Dorota Kurek,&nbsp;Amy C. Harms,&nbsp;Thomas Hankemeier,&nbsp;Floris Foijer,&nbsp;Terry G. J. Derks,&nbsp;Barbara M. Bakker","doi":"10.1002/jimd.70028","DOIUrl":"https://doi.org/10.1002/jimd.70028","url":null,"abstract":"<p>Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is an inherited metabolic disease, characterized by biallelic variants in the <i>ACADM</i> gene. Interestingly, even with the same genotype, patients often present with very heterogeneous symptoms, ranging from fully asymptomatic to life-threatening hypoketotic hypoglycemia. The mechanisms underlying this heterogeneity remain unclear. Therefore, there is a need for in vitro models of MCADD that recapitulate the clinical phenotype as a tool to study the pathophysiology of the disease. Fibroblasts of control and symptomatic MCADD patients with the c.985A&gt;G (p.K329E) were reprogrammed into induced pluripotent stem cells (iPSCs). iPSCs were then differentiated into hepatic expandable organoids (EHOs), further matured to Mat-EHOs, and functionally characterized. EHOs and Mat-EHOs performed typical hepatic metabolic functions, such as albumin and urea production. The organoids metabolized fatty acids, as confirmed by acyl-carnitine profiling and high-resolution respirometry. MCAD protein was fully ablated in MCADD organoids, in agreement with the instability of the mutated MCAD protein. MCADD organoids accumulated medium-chain acyl-carnitines, with a strongly elevated C8/C10 ratio, characteristic of the biochemical phenotype of the disease. Notably, C2 and C14 acyl-carnitines were found decreased in MCADD Mat-EHOs. Finally, MCADD organoids exhibited differential expression of genes involved in ω-oxidation, mitochondrial β-oxidation, TCA cycle, and peroxisomal coenzyme A metabolism, particularly upregulation of <i>NUDT7</i>. iPSC-derived organoids of MCADD patients recapitulated the major biochemical phenotype of the disease. Mat-EHOs expressed relevant pathways involved in putative compensatory mechanisms, notably CoA metabolism and the TCA cycle. The upregulation of <i>NUDT7</i> expression may play a role in preventing excessive accumulation of dicarboxylic acids in MCADD. This patient-specific hepatic organoid system is a promising platform to study the phenotypic heterogeneity between MCADD patients.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 3","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inborn Errors of Cell Trafficking and Complex Lipids: A Further Step in Redefining Hereditary Metabolic Disorders","authors":"Angeles García-Cazorla,&nbsp;Carlo Dionisi-Vici,&nbsp;Jean-Marie Saudubray","doi":"10.1002/jimd.70027","DOIUrl":"https://doi.org/10.1002/jimd.70027","url":null,"abstract":"&lt;p&gt;This special issue on Trafficking and Complex Lipid Metabolism represents a milestone in the evolution of Inherited Metabolic Disorders (IMD) as defined in the &lt;i&gt;Journal of Inherited Metabolic Disease&lt;/i&gt; (JIMD). Following the 2015 redefinition of IMD (Quo Vadis 2015), the last 10 years have brought a revolution in our understanding of IMD, reshaping definitions, concepts, paradigms, and classifications. This issue underscores the ubiquity of biochemical reactions in cellular processes, showing that many human genetic disorders, traditionally not classified as metabolic diseases, are rooted in biochemical disturbances.&lt;/p&gt;&lt;p&gt;Before 2015, JIMD primarily focused on disorders of intermediary metabolism and organelles, diagnosed using metabolic markers. In contrast, this special issue on trafficking disorders addresses disturbances in cellular machinery, diagnosed through molecular techniques that may lack measurable metabolic markers. Within each cell, biochemical functions are compartmentalized into organelles that work interdependently, forming a complex network where metabolites and biochemical pathways interact seamlessly. This “solidarity” between organelles—where changes in one impact others—is regulated by cellular trafficking, which facilitates the exchange of signals and metabolites between compartments.&lt;/p&gt;&lt;p&gt;This evolving understanding challenges metabolic physicians and clinical geneticists, who traditionally categorize genetic patients into inborn errors of metabolism (IEM) and dysmorphology cases. Practically, patients are often referred to separate genetic clinics based on this dual categorization. IEM is typically associated with metabolic markers (e.g., intoxication disorders, mitochondrial disorders), while dysmorphology patients are usually seen as those with congenital anomalies or intellectual disabilities. However, a holistic, integrative approach is increasingly essential to unravel the complexity of IMD mechanisms and phenotypes.&lt;/p&gt;&lt;p&gt;Today, the dual approach of IEM/dysmorphology in clinical genetics feels outdated. As many new monogenic genetic diseases emerge across specialties, notably in neurodevelopmental and neurodegenerative diseases, a broader framework is required. Cellular trafficking disorders exemplify how IMD can integrate diseases across various medical fields, offering a transversal discipline that connects cell trafficking mechanisms with biochemistry and symptomology. This integrative metabolic insight lays the groundwork for common treatments across different trafficking genes, similar to how mitochondrial disorders are managed with vitamins, cofactors, and specific diets, irrespective of the specific gene involved.&lt;/p&gt;&lt;p&gt;About 400 disorders, many of which present with multisystem phenotypes, are described in this special issue. Up to 85% of IMDs impact neurodevelopment or are responsible for neurodegeneration. Acute, chronic, or progressive neurological syndromes, psychiatric presentations, development","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 3","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLPB Deficiency, a Mitochondrial Chaperonopathy With Neutropenia and Neurological Presentation","authors":"D. Mróz,&nbsp;J. Jagłowska,&nbsp;R. A. Wevers,&nbsp;S. Ziętkiewicz","doi":"10.1002/jimd.70025","DOIUrl":"https://doi.org/10.1002/jimd.70025","url":null,"abstract":"&lt;p&gt;Human CLPB protein, a mitochondrial disaggregase, gained recognition in 2015, when four independent studies identified pathogenic variants in &lt;i&gt;CLPB&lt;/i&gt; as the underlying cause of a novel autosomal recessive multiorgan disorder presenting distinct laboratory findings, namely neutropenia and 3-methylglutaconic aciduria (ORPHA:445038; MIM #616271) [&lt;span&gt;1-4&lt;/span&gt;]. Biallelic &lt;i&gt;CLPB&lt;/i&gt; deficiency is a neurodevelopmental disorder with neutropenia and cataracts. More recently, certain monoallelic disease-causing germline variants were further identified as the cause of autosomal dominant &lt;span&gt;s&lt;/span&gt;evere &lt;span&gt;c&lt;/span&gt;ongenital &lt;span&gt;n&lt;/span&gt;eutropenia (CLPB-SCN; ORPHA:486; MIM #619813) [&lt;span&gt;5-7&lt;/span&gt;]. Newest in the field is the discovery that also a few monoallelic variants cause the same phenotype as in biallelic &lt;i&gt;CLPB&lt;/i&gt; defect with the exception of cataracts [&lt;span&gt;5&lt;/span&gt;] (MIM #619835).&lt;/p&gt;&lt;p&gt;The &lt;i&gt;CLPB&lt;/i&gt; gene is located on chromosome 11 (11q13.4) and consists of 19 exons. Four isoforms have been reported at the mRNA level, with two major isoforms reported at the protein level. The protein was named CLPB due to the surprising similarity between its AAA+ domain and the second AAA+ domain of bacterial ClpB (itself misnamed ‘Caseinolytic protease type B’ for similarity to ClpA protease, before it was characterised as a disaggregase without proteolytic activity) and its yeast orthologues Hsp104 and Hsp78 [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Though the study of the human protein gained momentum only recently, a mammalian CLPB orthologue was first described by Périer et al. [&lt;span&gt;8&lt;/span&gt;], where the expression of cDNA of the mouse CLPB homologue rescued the phenotype of the potassium-dependent yeast Trk- growth defect. The protein was thus named Skd3 (suppressor of K+ transport growth defect 3).&lt;/p&gt;&lt;p&gt;CLPB is a mitochondrial AAA+ (&lt;span&gt;&lt;i&gt;A&lt;/i&gt;&lt;/span&gt;TPases &lt;span&gt;&lt;i&gt;A&lt;/i&gt;&lt;/span&gt;ssociated with diverse cellular &lt;span&gt;&lt;i&gt;A&lt;/i&gt;&lt;/span&gt;ctivities) ATPase containing an HCLR-type (&lt;span&gt;&lt;i&gt;H&lt;/i&gt;&lt;/span&gt;slU, &lt;span&gt;&lt;i&gt;C&lt;/i&gt;&lt;/span&gt;lp-D2, &lt;span&gt;&lt;i&gt;L&lt;/i&gt;&lt;/span&gt;on and &lt;span&gt;&lt;i&gt;R&lt;/i&gt;&lt;/span&gt;uvB) ATPase domain characteristic for Hsp100 disaggregases. Similarly to those disaggregases, human CLPB in vitro solubilises aggregated luciferase, a model substrate and refolds it into enzymatically active form, implying a mitochondrial chaperone function [&lt;span&gt;9&lt;/span&gt;]. The ATPase domain is, however, preceded by a series of ankyrin repeats (Figure 1) which is an unprecedented feature in this group.&lt;/p&gt;&lt;p&gt;AAA+ proteins are involved in a wide variety of cellular processes, including proteolysis, DNA replication and repair, membrane fusion and protein unfolding and disaggregation. The proteins from this group usually form homohexameric rings and utilise the energy from ATP hydrolysis to thread their substrates through the central pore formed by the subunits. The characteristic feature of the ATPase domain of AAA+ proteins is the presence of Walker A (P-loop) and Walker","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 3","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia","authors":"Nicole H. Smith,&nbsp;Olivia S. Garrett,&nbsp;Emma Hendrickson,&nbsp;Jared J. Druss,&nbsp;Judith L. Fridovich-Keil","doi":"10.1002/jimd.70020","DOIUrl":"https://doi.org/10.1002/jimd.70020","url":null,"abstract":"<div>\u0000 \u0000 <p>Long-term complications are common among patients with classic galactosemia (CG) and show both reduced penetrance and variable expressivity. Overall prevalence rates for complications in cognitive, motor, and speech/voice/language outcomes among US and European cohorts are known. However, age at presentation, whether these complications cluster, and what factors might associate with penetrance remain unknown. These gaps in knowledge limit prognostic accuracy for young patients and leave open the question of whether complications in different outcome domains may have shared modifiers. Here we addressed these questions using data from medical records and family survey responses from 164 patients and 77 controls. We found that for cases who experienced long-term complications, the median age at presentation of challenges in cognitive outcome was about 5 years, in motor outcome was about 3 years, and in speech/voice/language outcome was about 2 years. We also found highly significant clustering of complications in these three domains. Finally, we tested six factors for possible association with penetrance: history of severe neonatal symptoms, <i>GALT</i> genotype and predicted residual GALT activity, days of neonatal milk exposure, rigor of non-dairy galactose restriction in early childhood, peak red blood cell (RBC) galactose-1P level in infancy, and baseline RBC galactose-1P level in early childhood. Of these, only history of severe neonatal brain-related symptoms consistently associated with higher penetrance, and only detectable predicted residual GALT activity consistently associated with lower penetrance. Combined, these results substantially extend what is known about the natural history of long-term complications in CG.</p>\u0000 </div>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 3","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Understanding of Pathogenic Mechanisms and Disease Models of Citrin Deficiency","authors":"Denis Lacabanne,&nbsp;Alice P. Sowton,&nbsp;Bosco Jose,&nbsp;Edmund R. S. Kunji,&nbsp;Sotiria Tavoulari","doi":"10.1002/jimd.70021","DOIUrl":"https://doi.org/10.1002/jimd.70021","url":null,"abstract":"<p>Citrin deficiency (CD) is a complex mitochondrial disease with three different age-related stages: neonatal intrahepatic cholestasis caused by CD (NICCD), failure to thrive and dyslipidemia caused by CD (FTTDCD), and type II citrullinemia (CTLN2), recently renamed adolescent and adult CD (AACD). While highly prevalent in the Asian population, CD is pan-ethnic and remains severely underdiagnosed. The disease is caused by the dysfunction or absence of the mitochondrial aspartate/glutamate carrier 2 (AGC2/SLC25A13), also known as citrin. Citrin deficiency results in a direct impairment of the malate–aspartate shuttle and the urea cycle, with expected knock-on effects on a multitude of other metabolic pathways, leading to a complicated pathophysiology. Here, we discuss our current knowledge of the molecular mechanism of substrate transport by citrin, including recent advances  suggesting against its calcium regulation. We also discuss the different types of pathogenic variants found in CD patients and new insights into their pathogenic mechanisms. Additionally, we provide a summary and assessment of the efforts to develop preclinical models as well as treatments for the disease.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate","authors":"Guenter Schwarz,&nbsp;Donald G. Basel,&nbsp;Bernd C. Schwahn,&nbsp;Ronen Spiegel,&nbsp;Flora Y. Wong,&nbsp;Robin Bliss,&nbsp;Liza Squires","doi":"10.1002/jimd.70000","DOIUrl":"https://doi.org/10.1002/jimd.70000","url":null,"abstract":"<p>Molybdenum cofactor deficiency (MoCD) Type A is an ultrarare disorder causing neurodegeneration and early death. Cyclic pyranopterin monophosphate (cPMP), a molybdenum cofactor precursor, is a therapeutic option for patients with MoCD Type A. In this study, efficacy in patients with MoCD Type A treated with recombinant cPMP (rcPMP) and/or fosdenopterin, a synthetic form of cPMP, from one retrospective and two prospective open-label studies (<i>N</i> = 14), was compared with a retrospective/prospective natural history study (untreated; <i>N</i> = 37). Safety was evaluated in treated patients. Patients treated with fosdenopterin/rcPMP had significantly reduced risk of premature/early death versus untreated patients (Cox proportional hazards 5.1; 95% CI 1.32–19.36; <i>p</i> = 0.01). MoCD disease biomarkers of urinary S-sulfocysteine and xanthine returned to near-normal from baseline to last visit in treated patients but remained abnormal in untreated patients. At 12 months, in treated patients, 43% could sit unassisted, 44% were ambulatory, and 57% could feed orally. Initiating fosdenopterin/rcPMP treatment ≤ 14 days after birth appeared to result in better clinical outcomes than initiating &gt; 14 days after birth. Most patients (13/14) had a treatment-emergent adverse event; most were unrelated to fosdenopterin/rcPMP, were mild to moderate in severity, and none led to treatment discontinuation. These results demonstrate that patients with MoCD Type A who received fosdenopterin/rcPMP versus untreated patients were more likely to survive. Some treated patients were able to feed orally and achieve developmental milestones including walking. Fosdenopterin/rcPMP was generally well-tolerated. Improved outcomes in patients treated early support the importance of identifying MoCD in neonates and initiating treatment as soon as possible.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis”","authors":"","doi":"10.1002/jimd.70023","DOIUrl":"https://doi.org/10.1002/jimd.70023","url":null,"abstract":"<p>A. Pisani, K. M. Wilson, J. L. Batista, et al., “Clinical Outcomes in Patients Switching from Agalsidase Beta to Migalastat: A Fabry Registry Analysis,” <i>Journal of Inherited Metabolic Disease</i> 47, no. 5 (2024): 1080–1095, https://doi.org/10.1002/jimd.12773.</p><p><i>Note:</i> For each outcome, the model includes patients with at least 1 record in each of the pre- and post-switch periods; sample sizes are the same as those shown for Classic and Late-onset patients in Table 2. Each model includes interaction terms to allow slopes to vary by time period (pre/post switch) and phenotype, is adjusted for age at switch date (continuous) and sex, and includes random intercepts. To visually display estimated trajectories over time for each phenotype, estimated values are shown for a male, aged 50 years at the switch date. The slopes of the lines indicate the estimated annual change in the outcome during each time period. Estimated slopes are the same regardless of sex or age.</p><p>We apologize for this error.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Never-Treated, Non Splenectomised Patients With Gaucher Disease (The French GANT Study): The Prospective Follow-Up","authors":"Alberto Nasce,&nbsp;Yann Nguyen,&nbsp;Nadia Belmatoug,&nbsp;Karima Yousfi,&nbsp;Fabrice Camou,&nbsp;Magali Pettazzoni,&nbsp;Florence Dalbies,&nbsp;Bérengère Cador,&nbsp;Anaïs Brassier,&nbsp;Samia Pichard,&nbsp;Bénédicte Hivert,&nbsp;Laure Swiader,&nbsp;Ivan Bertchansky,&nbsp;Vanessa Leguy Seguin,&nbsp;Wladimir Mauhin,&nbsp;Leonardo Astudillo,&nbsp;Isabelle Hau Rainsard,&nbsp;Sébastien Humbert,&nbsp;Celia Hoebeke,&nbsp;Dalil Hamroun,&nbsp;Agathe Masseau,&nbsp;Marc G. Berger,&nbsp;Jérôme Stirnemann,&nbsp;Christine Serratrice,&nbsp;Comité d'Evaluation et de Traitement de la maladie de Gaucher (CETG)","doi":"10.1002/jimd.70026","DOIUrl":"10.1002/jimd.70026","url":null,"abstract":"<div>\u0000 \u0000 <p>Treatment options for Type 1 Gaucher Disease (GD1) include enzyme replacement therapy and oral substrate reduction therapy. The criteria for treatment initiation vary across regions. Recent retrospective studies have highlighted the natural progression of never-treated GD1, suggesting that some patients remain asymptomatic or stable for extended periods. However, there is no data on long-term prospective follow-up. We conducted a prospective study following a cross-sectional analysis of 36 never-treated, non-splenectomised GD1 patients from the French Gaucher Disease Registry (FGDR). The objective was to describe the natural disease progression, tracking clinical, radiological, and biological characteristics over time. Thirty-six non-splenectomised and never-treated patients (19 women and 17 men) diagnosed with Gaucher Disease were prospectively followed for an additional median duration of 6.5 (5–8.3) years. Of the cohort, 17 remained untreated, 10 initiated treatment, and 7 were lost to follow-up. Although never-treated patients tended to be older at the time of first symptoms, diagnosis, and last follow-up compared to those who received treatment, the difference was not significant in this small cohort. At last follow-up, never-treated patients had no worsening of most of their symptoms. No significant changes were observed in platelets, chitotriosidase, and lyso-Gb1. In this prospective cohort, we highlight that patients with mild GD can remain untreated with no disease progression, offering insights into cost-effective management strategies. Identifying such patients is still challenging.</p>\u0000 </div>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycerophospholipids: Roles in Cell Trafficking and Associated Inborn Errors","authors":"Foudil Lamari,&nbsp;Francis Rossignol,&nbsp;Grant A. Mitchell","doi":"10.1002/jimd.70019","DOIUrl":"https://doi.org/10.1002/jimd.70019","url":null,"abstract":"<p>Glycerophospholipids (GPLs) are the main lipid components of cellular membranes. They are implicated in membrane structure, vesicle trafficking, neurotransmission, and cell signalling. GPL molecules are amphiphilic, organized around the three carbons of glycerol. Positions <i>sn-1</i> and <i>sn-2</i> are each esterified to a fatty acid (FA). At position <i>sn-3</i>, a phosphate group is linked, which in turn can bind a polar head group, the most prevalent classes being phosphatidic acid (PA, phosphate alone as head group), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and cardiolipin (CL). Pathways of GPL biosynthesis span several cell compartments (endoplasmic reticulum (ER), Golgi mitochondria). Particularly important are mitochondria-associated membranes (MAMs), where the ER and mitochondrial outer membrane are in proximity. After synthesis, GPLs continuously undergo remodelling by FA hydrolysis and re-esterification. Esterification with different FAs alters membrane properties. Many steps in GPL synthesis and remodelling can be mediated by more than one enzyme, suggesting complexity that requires further exploration. The 38 known GPL-related inborn errors are clinically diverse. 23 (61%) have neurologic features, sometimes progressive and severe, particularly developmental delay/encephalopathy in 16 (42%) and spastic paraplegia in 12 (32%). Photoreceptor/neuroretinal disease occurs in 14 (37%). Three present skeletal dysplasias (8%). Most GPL inborn errors have been diagnosed by broad molecular testing. Lipidomics holds promise for diagnostic testing and for the discovery of functionally relevant metabolite profiles for monitoring natural history and treatment response.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Comparative Analysis of Gene and Disease Selection in Genomic Newborn Screening Studies”","authors":"","doi":"10.1002/jimd.70022","DOIUrl":"https://doi.org/10.1002/jimd.70022","url":null,"abstract":"<p>I. R. Betzler, M. Hempel, U. Mütze, et al., “Comparative Analysis of Gene and Disease Selection in Genomic Newborn Screening Studies,” <i>Journal of Inherited Metabolic Disease</i> 47, no. 5 (2024): 945–970, https://doi.org/10.1002/jimd.12750.</p><p>It has come to our attention that our original article contained errors in the mapping of ClinGen's Gene-Disease Validity data to gene lists from genomic newborn screening studies. Specifically, Table 2 mistakenly included the genes <i>MAGT1</i>, <i>CACNA1C</i>, <i>GJA1</i>, <i>KCNJ5</i>, <i>NOTCH3</i>, and <i>RASA1</i>, which were assigned to phenotypes primarily listed in ClinGen rather than those considered in the gNBS panels.</p><p>These corrections do not alter the overall conclusions of our study but clarify the challenges involved in defining target diseases for gNBS. We sincerely appreciate the constructive feedback from our colleagues and apologize for this error. We remain committed to transparency and accuracy in genomic newborn screening research.</p>","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}